Document is current

Article History

Received: 29 October 2025

Accepted: 15 February 2026

First Online: 12 March 2026

Declarations

:

: BH, AH, JC, DR, MR, and SD are employees of Pfizer and may hold stocks/stock options for Pfizer, which sponsored this review and the development of this publication. VW is an employee of RTI Health Solutions and is an Editorial Board Member of The Patient . She was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. SC has previously been a consultant for Pfizer. NA reports no honoraria related to this work and reports travel support from Pfizer, Exelixis, and Johnson & Johnson to attend meetings of the respective pharmaceutical companies. Research funding has been provided to NA’s institution by the following: Arnivas, Astellas, Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.

: The data that support the findings of this literature review are available in the article itself or its supporting information.

: All authors made a significant contribution to this work, whether that is in the conception, study design, execution, analysis, or interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.